The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Safety and efficacy of intravenous iron administration for uterine bleeding or postpartum anaemia: a narrative review.

TitleSafety and efficacy of intravenous iron administration for uterine bleeding or postpartum anaemia: a narrative review.
Publication TypeJournal Article
Year of Publication2018
AuthorsDaniilidis, A., Panteleris N., Vlachaki E., Breymann C., & Assimakopoulos E.
JournalJ Obstet Gynaecol
Volume38
Issue4
Pagination443-447
Date Published2018 May
ISSN1364-6893
KeywordsAdministration, Intravenous, Administration, Oral, Anemia, Iron-Deficiency, Female, Hematinics, Humans, Iron Compounds, Pregnancy, Puerperal Disorders, Treatment Outcome
Abstract

The management of iron deficiency anaemia (IDA) consists of oral or intravenous administration of iron supplements. The aim of this narrative review is to summarise information regarding the treatment of IDA in women who have postpartum anaemia or uterine bleeding with intravenous (IV) or oral iron supplements. Fourteen randomised control studies comparing IV to oral iron treatment for IDA in 2913 women with uterine bleeding or postpartum haemorrhage are included. All reviewed studies suggest that IV iron administration is important in treating the IDA in such women and in improving their physical performance and quality of life. Comparisons among intravenous iron supplements show advantages of ferric carboxymaltose over others in time of reaching desired haemoglobin and ferritin values and in adverse reactions. Despite the limitation that the above evidence emerges from not systematically collected data, our review highlights that new forms of IV iron supplements seem safe and efficient in treating IDA.

DOI10.1080/01443615.2017.1363170
Alternate JournalJ Obstet Gynaecol
PubMed ID29057687

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.